Recent studies reveal critical mechanisms of drug resistance and novel therapeutic strategies across multiple cancers. UT Health San Antonio researchers uncovered the CST complex’s role in PARP inhibitor resistance in BRCA1-deficient tumors, highlighting DNA repair pathway adaptation. City of Hope received $23.7 million for biomarker mapping of immunotherapy resistance in lung cancer. MD Anderson distinguished lymphoma microenvironment subtypes predicting CAR T-cell therapy response. Additionally, innovations include Naya Therapeutics' targeted radiotherapy for hepatocellular carcinoma and Aptevo's bispecific antibody achieving 85% remission in AML. These advances span from molecular biology to clinical trials, promising enhanced precision oncology.